EP
RYTM icon

Essential Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Essential Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.55K Sell
77
-43
-36% -$3.89K ﹤0.01% 1294
2026
Q1 		$10.4K Sell
120
-103
-46% -$10K ﹤0.01% 1237
2025
Q4 		$23.9K Buy
223
+25
+13% +$2.65K 0.01% 843
2025
Q3 		$20K Buy
198
+78
+65% +$7.24K 0.01% 889
2025
Q2 		$7.58K Buy
+120
New +$7.35K ﹤0.01% 930

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Essential Partners's RYTM Position: Q2 2026 in Review

Essential Partners reduced its Rhythm Pharmaceuticals (RYTM) stake by 36% in Q2 2026, selling an estimated $3.89K and leaving 77 shares worth $8.55K. The position accounts for ﹤0.01% of the portfolio, ranked #1294.

Essential Partners first reported a position in RYTM in Q2 2025 and has held it in 5 quarters since. The position peaked at $23.9K in Q4 2025. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Essential Partners held 77 shares of Rhythm Pharmaceuticals worth $8.55K as of Q2 2026.
  • Essential Partners sold 43 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $3.89K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1294 holding.
  • Essential Partners first reported a position in Rhythm Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Rhythm Pharmaceuticals position peaked at $23.9K in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.